Akebia Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference
Akebia Therapeutics (Nasdaq: AKBA), a biopharmaceutical company dedicated to improving the lives of individuals affected by kidney disease, will participate in the 39th Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Akebia Therapeutics (Nasdaq: AKBA), a biopharmaceutical company dedicated to improving the lives of individuals affected by kidney disease, will participate in the 39th Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for January 13, 2021, at 2:50 p.m. EST, led by John P. Butler, President and CEO. Interested parties can access the live webcast and replay on the Investors section of Akebia's website. Founded in 2007 and based in Cambridge, Massachusetts, Akebia is focused on developing therapeutics for kidney disease.
Details
News Market Reaction – AKBA
The recorded move for AKBA in the trading session of this news was +4.46%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Jan. 4, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, President and Chief Executive Officer, will present virtually at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, at 2:50 p.m. EST.
A live webcast and replay of Akebia's presentation and associated Q&A will be available on the Investors section of the Company's website at https://ir.akebia.com.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. The Company was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.
Akebia Therapeutics Contact
Kristen K. Sheppard, Esq.
ir@akebia.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/akebia-therapeutics-to-present-at-39th-annual-jp-morgan-healthcare-conference-301199899.html
SOURCE Akebia Therapeutics
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.